Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction
Provided By GlobeNewswire
Last update: Jan 27, 2025
-- Study met primary endpoint: Enobosarm treatment resulted in statistically significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) --
Read more at globenewswire.com0.5229
-0.01 (-2.12%)
Find more stocks in the Stock Screener
VERU Latest News and Analysis
20 days ago - ChartmillWhich stocks are experiencing notable movement on Tuesday?Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.
20 days ago - ChartmillLet's uncover which stocks are experiencing notable gaps during today's session.There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.
